Schaeffer A J
Am J Med. 1987 Jun 26;82(6B):53-8. doi: 10.1016/0002-9343(87)90619-x.
A multicenter open study of 477 patients with urinary tract infections was undertaken. The patients were treated with 400 mg of norfloxacin twice daily for seven to 30 days. Four hundred eight (98 percent) of 417 gram-negative organisms and 58 (94 percent) of 62 gram-positive organisms were susceptible to norfloxacin. The infecting organisms were eradicated in 276 of 307 evaluable patients (90 percent). Of the 31 bacteriologic failures, two organisms were initially resistant to norfloxacin and four organisms acquired resistance to norfloxacin and persisted despite treatment. Twenty-eight patients (10 percent) had recurrent infections; 24 of the 25 organisms involved in these infections were susceptible to norfloxacin. Seventeen patients (3.5 percent) experienced clinical adverse effects that were probably or definitely related to the drug. One adverse reaction was serious. Although norfloxacin was discontinued in two patients because of clinical side effects, none of the patients experienced laboratory adverse effects that were either serious or drug related.
对477例尿路感染患者进行了一项多中心开放性研究。患者接受每日两次400毫克诺氟沙星治疗，疗程为7至30天。417株革兰氏阴性菌中的408株（98%）和62株革兰氏阳性菌中的58株（94%）对诺氟沙星敏感。307例可评估患者中有276例（90%）的感染菌被根除。在31例细菌学治疗失败病例中，有2株菌最初对诺氟沙星耐药，4株菌获得了对诺氟沙星的耐药性，尽管进行了治疗仍持续存在。28例患者（10%）出现了复发性感染；这些感染中涉及的25株菌中有24株对诺氟沙星敏感。17例患者（3.5%）出现了可能或肯定与药物相关的临床不良反应。其中1例不良反应较为严重。尽管有2例患者因临床副作用停用了诺氟沙星，但没有患者出现严重的或与药物相关的实验室不良反应。
